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Active transforming growth factor‑β1 (TGF‑β1), a cytokine partially regulated by hypoxia and obesity, 
has been related with poor prognosis in several tumors. We determine whether obstructive sleep 
apnea (OSA) increases serum levels of active TGF‑β1 in patients with cutaneous melanoma (CM), 
assess their relationship with melanoma aggressiveness and analyze the factors related to TGF‑β1 
levels in obese and non‑obese OSA patients. In a multicenter observational study, 290 patients with 
CM were underwent sleep studies. TGF‑β1 was increased in moderate‑severe OSA patients vs. non‑
OSA or mild OSA patients with CM. In OSA patients, TGF‑β1 levels correlated with mitotic index, 
Breslow index and melanoma growth rate, and were increased in presence of ulceration or higher 
Clark levels. In CM patients, OSA was associated with higher TGF‑β1 levels and greater melanoma 
aggressiveness only in non‑obese subjects. An in vitro model showed that IH‑induced increases of 
TGF‑β1 expression in melanoma cells is attenuated in the presence of high leptin levels. In conclusion, 
TGF‑β1 levels are associated with melanoma aggressiveness in CM patients and increased in 
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moderate‑severe OSA. Moreover, in non‑obese patients with OSA, TGF‑β1 levels correlate with OSA 
severity and leptin levels, whereas only associate with leptin levels in obese OSA patients.
The putative association between obstructive sleep apnea (OSA) and cutaneous melanoma (CM)  aggressiveness1,2, 
a malignant tumor which despite substantial progress in therapy retains high mortality rates, has been rein-
forced by improved identification of biologically plausible pathophysiological pathways. OSA effects on tumor 
development and progression have been mainly attributed to the impact of intermittent hypoxia on the local 
tumor microenvironment, promoting melanoma cell proliferation, the release of pro-angiogenic factors, and 
alterations of the immune surveillance  system1,3–5. However, the impact of OSA on the intrinsic properties of 
tumor cells is less well understood.
There is increasing evidence that the aggressiveness of CM is largely due to the intrinsic plasticity of mela-
noma cells, which is regulated by a variety of mechanisms that prominently include the transforming growth 
factor-β (TGF-β)  pathway6,7. TGF-β is a multi-factorial peptide growth factor that is synthesized by macrophages, 
lymphocytes, fibroblasts, platelets, epithelial and cancer cells, and plays a key role in the regulation of several 
physiological processes, including cell proliferation, differentiation, migration, adhesion, and tissue  repair8. 
TGF-β synthesized forms a dimer of with a latency-associated peptide, remaining inactive and anchored in the 
extracellular matrix by the TGF-ß binding proteins. TGF-ß activation requires its release form the extracellular 
matrix by proteolytic  cleavage9. To adequately evaluate serum TGF-ß, it is important to consider that most of it 
corresponds to the latent complex form, while only a small fraction is biologically  active10.
In melanoma cells, extracellular active TGF-β regulates gene expression by receptor-mediated activation of 
SMAD (an acronym from the fusion of Caenorhabditis elegans Sma genes and the Drosophila Mad, Mothers 
against decapentaplegic) transcription factors that regulate the transcriptional output of active genes and can 
also open repressive  chromatin7. Among the several TGF-β isoforms, TGF-β1 has been shown to be expressed 
by melanoma cells and to promote invasiveness in cell  cultures11, whereas attenuation of TGF-β signaling by 
treatment with a small molecule inhibitor reduced bone metastasis  formation12. Although a previous study did 
not identify a relationship between serum TGF-ß1 concentration and melanoma  stage13, probably because cir-
culating bioactive TGF-β1 levels were not specifically measured, it has been demonstrated that overall canonical 
TGF-β/SMAD signaling is a potent promoter of melanoma progression, even at early stages of the  disease14, and 
that soluble active TGF-β1 is directly related to the risk of melanoma  metastasis15,16.
The involvement of the TGF-β/SMAD pathway in melanoma progression could be potentially important 
in OSA patients, since previous studies have shown that increased hypoxia-induced factor (HIF) secondary to 
hypoxia induces the activation of the TGF-β1/SMAD signaling  pathway17–19. Along the same line, it has been 
described that patients with severe OSA have higher circulating levels of active TGF-β1 than control subjects, 
which decreases after six months of CPAP  treatment20. Interestingly, it has also been reported that leptin synthe-
sized and secreted by adipose tissues, after binding to its specific receptor on tumor cells, activates an intracellular 
signaling pathway that recruits transcription factors to the promoter of the TGF-β1 gene, increasing synthesis 
and secretion of TGF-β1 by tumor  cells21.
Circulating TGF-β1 levels have been shown to exhibit dependency on both intermittent hypoxia and obesity 
(mediated through serum leptin levels)19,21–23, and such observations lead to the question whether OSA may 
have any effect on the activation of the TGF-β1/SMAD pathway in patients with melanoma, and if so, whether 
there is any synergistic effect with obesity. Therefore, our study objectives were to compare serum levels of active 
TGF-β1 in patients with CM according to the presence and severity of OSA, assess the correlation between active 
TGF-β1 levels and melanoma aggressiveness indices, and analyze their relationship with nocturnal hypoxia and 
serum levels of leptin in both obese and non-obese patients. Moreover, we explored the leptin effect on TGF-β1 
released by melanoma cells under intermittent hypoxia in an in vitro model of OSA.
Results
The general characteristics of the study participants are shown in Table 1. We included 290 patients, 146 of which 
were men, with a median (IQR) age of 55 (44–69) years and a mean BMI of 27.0 (24.2–29.7) Kg m−2. Local 
melanoma extension was detected in 250 patients (87%), and evidence of ulceration was found in 49 (17%). 
Median (IQR) Breslow and mitotic indices were 0.84 (0.50–1.93) mm and 1 (0–2) cells mm−2, respectively; while 
the growth rate was 0.15 (0.05–0.45) mm month−1. The overall prevalence rates of mild and moderate-to-severe 
OSA were 31.7 and 33.8%, respectively. The comparison between groups illustrates that, as the severity of OSA 
increases, patients were increasingly more likely to be men, older and more obese.
Active TGF‑β1 is increased in moderate‑severe OSA patients and correlates with melanoma 
aggressiveness. Active TGF-β1 serum levels showed significant differences among the three study sub-
groups (p < 0.001). When adjusted for sex, age, BMI and neck circumference, TGF-β1 serum levels were higher 
in moderate-severe OSA patients versus mild OSA or non-apneic patients (Fig. 1A).
In OSA patients, active TGF-β1 levels exhibited a strong relationship with mitotic index (r = 0.405, p < 0.001), 
Breslow index (r = 0.419, p < 0.001) and melanoma growth rate (r = 0.309, p < 0.001) (Fig. 2). OSA patients with 
locoregional disease had higher TGF-β1 levels than those with localized melanoma (9.64 [3.91–14.29] vs. 4.54 
[2.35–9.04] pg mL−1, p = 0.008). TGF-β1 levels were also higher in OSA patients with ulceration of melanoma 
than in those without ulceration (9.07 [4.03–21.67] vs. 4.21 [2.09–8.75] pg mL−1, p = 0.001). Finally, differences 
in TGF-β1 levels according to Clark levels were also detected (p < 0.001) (Fig. 2).
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Leptin levels and OSA patient characteristics according to obesity. No significant differences in 
leptin levels were found among the melanoma patients without OSA and those with mild or moderate-severe 
OSA (Fig. 1B). In the OSA patients overall, leptin levels weakly correlated with melanoma growth rate (r = 0.192, 
p = 0.008) and Breslow index (r = 0.140, p = 0.054).
As would be anticipated, leptin levels were higher in obese than in non-obese OSA patients (4.49 [3.59–5.26] 
vs. 3.36 [2.38–4.68] ng mL−1, p = 0.001), whereas active TGF-β1 levels did not differ between subgroups of OSA 
patients (Table S1). In addition, among obese OSA patients there was a lower predominance of males as well as 
a greater severity of apneas-hypopneas and nocturnal hypoxemia when compared to nonobese OSA cases, but 
no significant differences in melanoma aggressiveness were identified.
TGF‑β1 levels only are related to OSA severity in non‑obese patients. Table 2 shows the correla-
tion between active TGF-β1 levels, polygraphic parameters and leptin levels in OSA patients with or without 
obesity. In non-obese OSA patients, TGF-β1 levels correlated with leptin levels as well as with AHI, desaturation 
index, lowest nocturnal oxygen saturation and time with  SpO2 < 90%. In the multivariate stepwise regression 
model, AHI and leptin levels were retained as independent predictors of TGF-β1 levels (Table  3, Fig.  3). In 
contrast, in obese patients with OSA, TGF-β1 levels were only significantly related to leptin levels (Fig. 3). A 
sensitivity analysis using different BMI cut-off points (ranging from 28 to 33 kg m−2) showed similar results.
When all obese patients with CM were analyzed together, the presence of OSA was not associated with higher 
levels of TGF-β1 or with greater tumor aggressiveness. In contrast, non-obese patients with OSA exhibited 
higher levels of TGF-β1 and melanoma aggressiveness indices (Table S2). The correlation between serum levels 
Table 1.  General characteristics of the study subjects. Data are presented as median (interquartile range 
[IQR]) or n (%) and significant differences are highlighted in bold. BMI body mass index; ESS Epworth 
sleepiness score; AHI apnea–hypopnea index; ODI desaturation index; SaO2 oxygen saturation; tSaO2 < 90% 
night time spent with oxygen saturation < 90%; TGF-β1 tumor growth factor- β1.
Non OSA patients Mild OSA patients Moderate-severe OSA patients P
N 100 92 98 -
Males, n (%) 36 (36) 44 (48) 66 (67)  < 0.001
Age (years) 41 (36–49) 57 (44–73) 68 (59–76)  < 0.001
BMI (Kg m−2) 24.3 (22.6–27.2) 28.4 (24.9–31.5) 28.3 (26.6–32.3)  < 0.001
Neck circumference (cm) 36 (33–39) 37 (35–39) 40 (37–43)  < 0.001
Obesity, n (%) 7 (7) 27 (29) 37 (38)  < 0.001
Smoking status, n (%) 0.456
 Never 47 (47) 51 (55) 50 (51)
 Current smoker 23 (23) 15 (16) 14 (14)
 Past smoker 30 (30) 26 (28) 34 (35)
Type of melanoma, n (%) 0.606
 Superficial spreading melanoma 76 (76) 67 (73) 62 (64)
 Lentigo maligna melanoma 5 (5) 6 (7) 12 (12)
 Acral lentiginous melanoma 4 (4) 5 (5) 5 (5)
 Nodular melanoma 14 (14) 14 (15) 17 (18)
 Other 1 (1) - 1 (1)
Mitotic index, (cells mm−2) 1 (0–2.5) 1 (0–3) 1 (0–5) 0.055
Breslow index (mm) 0.75 (0.51–1.38) 0.80 (0.51–2.20) 1.20 (0.70–3.00)  < 0.001
Ulceration, n (%) 8 (8) 20 (22) 51 (21) 0.014
Growth rate, (mm month−1) 0.11 (0.06–0.34) 0.14 (0.06–0.27) 0.38 (0.08–0.89) 0.005
Clark index 3 (2–3.5) 3 (2–4) 3 (3–4) 0.004
Disease stage, n (%) 0.048
 Localized melanoma 92 (93) 80 (88) 78 (81)
 Locoregional disease 7 (7) 11 (12) 18 (19)
ESS score 7 (3–9) 6 (4–7) 6 (4–9) 0.353
AHI  (h−1) 2.0 (0.7–2.9) 8.6 (6.8–11.2) 29.8 (21.6–46.0)  < 0.001
ODI  (h−1) 0.9 (0.3–1.4) 5.0 (2.6–6.8) 29.8 (21.6–46.0)  < 0.001
Mean nocturnal  SaO2 (%) 94 (93–96) 93 (92–95) 93 (92–94)  < 0.001
Low nocturnal  SaO2 (%) 89 (86–91) 81 (78–88) 79 (75–85)  < 0.001
tSaO2 < 90% (%) 0.0 (0.0–0.6) 1.7 (0.1–8.4) 4.5 (1.0–13.1)  < 0.001
Leptin (ng mL−1) 3.80 (2.29–4.67) 3.60 (2.69–5.21) 3.95 (2.91–5.10) 0.131
TGF-β (pg mL−1) 3.91 (2.08–7.59) 3.71 (0.98–9.44) 4.78 (2.09–11.42) 0.001
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of active TGF-β1 and melanoma aggressiveness indices was maintained after considering obese and non-obese 
OSA patients separately (Table S3).
In vitro effect of intermittent hypoxia on TGF‑β1 expression is modulated by leptin levels. IH 
exposures in vitro increased bioactive TGF-β1 levels in the culture supernatant of melanoma cells subjected 
to the lowest leptin concentration, while such effect disappeared with the higher leptin concentration (Fig. 4). 
TGF-β1 expression assessed by mRNA showed a similar trend, although it did not reach statistical significance 
(Fig. S1).
Discussion
In patients with cutaneous melanoma, moderate-severe OSA is associated with increased circulating levels of 
active TGF-β1 which correlate with tumor aggressiveness. In addition, while TGF-β1 levels are independently 
related to serum leptin and AHI in non-obese subjects, they associate with leptin levels only in obese subjects, 
suggesting that the potential contribution of OSA to increase active TGF-β1 may be limited to non-obese patients. 
Moreover, the in vitro melanoma cell culture model showed that the IH-induced increase of active TGF-β1 
expression is attenuated by the presence of higher leptin levels.
The TGF-β pathway plays a major role in the evolution of cancer, and has been implicated with tumor pro-
gression by driving epithelial mesenchymal transition, tumor cell migration, invasion, metastatic spread and 
 angiogenesis24. The roles of TGF-β1 have been more extensively investigated relative to other isoforms of TGF-β. 
Figure 1.  Box-and-whisker plots depicting the distribution of: (A) serum levels of active TGF-β1; and (B) 
leptin, in cutaneous melanoma patients according to their apnea–hypopnea index. Data are presented as median 
(interquartile range), maximum and minimum values, and overall comparisons were performed using the 
Kruskal–Wallis test. #p-values corresponding to the post hoc comparisons between groups adjusted for sex, age, 
body mass index and neck circumference. OSA obstructive sleep apnea.
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Figure 2.  Relationship of serum levels of active TGF-β1 with the mitotic index (A), Breslow index (B) and 
melanoma growth rate (C) in patients with cutaneous melanoma and OSA. (D) Comparison of TGF-β1 levels 
according Clark level in the OSA patients with cutaneous melanoma.
Table 2.  Anthropometric and sleep parameters related with active TGF-β1 serum levels in the non-obese 
and obese OSA patients. BMI body mass index; ESS Epworth sleepiness score; AHI apnea–hypopnea index; 
DI desaturation index; SpO2 oxygen saturation; tSpO2 < 90% night time spent with oxygen saturation < 90%; r 
Spearman correlation coefficient; CI confidence interval.
Non-obese OSA patients Obese OSA patients
r 95%CI p r 95%CI p
Age (years) 0.013 − 0.168 to 0.193 0.887 0.301 0.053 to 0.514 0.018
BMI (Kg m−2) 0.020 − 0.161 to 0.200 0.828 − 0.029 − 0.279 to 0.224 0.825
Neck circumference (cm) − 0.055 − 0.233 to 0.127 0.555 0.203 − 0.051 to 0.433 0.116
ESS − 0.145 − 0.317 to 0.037 0.116 0.105 − 0.151 to 0.348 0.420
AHI  (h−1) 0.241 0.063 to 0.404 0.008 0.225 − 0.028 to 0.451 0.081
DI  (h−1) 0.215 0.036 to 0.381 0.025 0.059 − 0.196 to 0.306 0.651
Mean nocturnal  SpO2 (%) − 0.102 − 0.278 to 0.080 0.273 − 0.007 − 0.258 to 0.245 0.956
Low nocturnal  SpO2 (%) − 0.236 − 0.400 to − 0.058 0.014 − 0.067 − 0.314 to 0.188 0.605
tSpO2 < 90% (%) 0.208 0.028 to 0.375 0.045 0.085 − 0.170 to 0.330 0.512
Leptin serum levels (ng mL−1) 0.206 0.026 to 0.373 0.025 0.413 0.180 to 0.602 0.001
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When bound to a specific receptor on the target cell membrane, TGF-β1 activates TGF-β receptor type I kinase, 
resulting in the phosphorylation of SMAD2 and SMAD3, which subsequently form oligomeric complexes with 
SMAD4, and translocate to the nucleus to regulate the expression of a large repertoire of  genes21,25. In light of 
the biological roles of TGF-β1 in cancer, the strong relationships between serum levels of active TGF-β1 and 
all indices of melanoma aggressiveness in OSA patients are therefore not unexpected. The increased TGF-β1 
levels identified in patients with moderate-severe OSA indicate that this disorder has an incremental effect on 
the expression and release of active TGF-β1 even in patients who have already developed a melanoma. Currently 
available evidence suggests that this effect is likely due to the OSA-related intermittent hypoxia. In fact, TGF-β1 
has been shown to be increased in a variety of cells cultured in hypoxia and also in hypoxic ischemic  tissues26. 
Several reports show that hypoxia activates latent TGF-β1 via HIF-1α in hepatocytes, placental fibroblasts, pri-
mary human lung fibroblasts, smooth muscle cells and cancer  cells22,26. Using in vitro models, it has been recently 
confirmed that HIF-1α induction by hypoxia promotes the expression of TGF-β1, activates its receptors, and 
increases the phosphorylation of the SMAD2/3 proteins, indicating an activation of the TGF-β/SMAD signaling 
pathway, probably through the TLR/MyD88/NF-κB  pathway23.
Although our results do not establish causal inferential mechanisms, the correlation found between the dif-
ferent nocturnal hypoxemia indices and the levels of active TGF-β1 among patients with OSA and melanoma 
concurs with the potential relevance of intermittent hypoxia in the enhanced induction of TGF-β1. The selec-
tion of AHI instead of the nocturnal hypoxemia indices by the multiple regression model could be due solely to 
the limited number of patients with more severe OSA (cutaneous melanoma was the driving selection criterion 
rather than OSA). However, it is also not possible to exclude that other OSA-related perturbations contribute 
to TGF-β1 production. Indeed, in a murine model exposed to intense sleep fragmentation, increases in TGF-β1 
expression in the hypothalamus and hippocampus were  reported27.
Leptin is primarily produced by fat cells and regulates food intake, energy homeostasis and cell  proliferation28. 
High serum levels of leptin, which are strongly correlated with adipose tissue mass, are recognized as a factor 
driving cancer development and progression, as leptin exhibits mitogenic, proinflammatory, anti-apoptotic, and 
proangiogenic  properties28–31. The finding of a significant relationship between leptin and TGF-β1 levels in our 
patients is consistent with previous studies that showed that leptin binds to leptin receptors on the surface of 
cancer cells, activates JAK/STAT3 signaling, and consequently increases TGF-β  expression21. Moreover, it has 
been demonstrated that leptin can be a co-factor for TGF-β in cancer using an in vitro model of kidney fibroblasts 
whereby leptin treatment enhances SMAD2/3 phosphorylation by TGF-β32,33. Interestingly, the relationship 
between leptin and TGFβ could be bidirectional, since TGFβ/SMAD3 signaling appears to be crucial for the 
development of obesity, as demonstrated in mice in which TGFβ signaling was blocked or that were deficient 
in SMAD3 and consequently were protected from developing  obesity34,35. Additionally, other members of the 
TGF-β family are involved in regulation of adipogenesis and energy metabolism through SMAD and P38 signal-
ing  pathways36.
There is substantial evidence on the association between obesity and increased cancer risk and  metastasis37. 
It has been estimated that roughly 20% of all cancers are caused by excess weight  gain38,39 and, although the 
mechanisms are unclear, some studies have suggested that obesity enhances metastases in tumors such as mela-
noma, colon, lung and breast  cancer40,41. In fact, there is greater risk of recurrence among cancer patients with 
higher  BMI42, and cancer patients with high BMI have higher mortality rates compared to those with average 
 BMI38. Although in our subgroup of patients with OSA and melanoma the differences in Breslow index between 
obese and non-obese subjects did not reach statistical significance (Table S1) (probably due to sample size), in 
the overall cohort, those who were obese had a higher Breslow index compared to non-obese (1.10 [0.60–2.15] 
vs. 0.80 [0.47–1.70] mm, p = 0.015), further reinforcing the observation that obesity is associated with greater 
melanoma aggressiveness.
The most striking finding in the present study is that the correlation between AHI and nocturnal hypoxemia 
indices with the serum levels of active TGF-β1 among OSA patients reached statistical significance only in non-
obese subjects, while in the obese the serum leptin concentration was the only independent variable associated 
with TGF-β1 levels. Moreover, the results of our in vitro model confirmed that intermittent hypoxia-induced 
elevations in active TGF-β1 expression in melanoma cells are attenuated by higher leptin levels. In this context, 
Table 3.  Independent predictors of serum levels of active TGF-β1 in obese and non-obese OSA patients with 
melanoma. AHI apnea–hypopnea index; S.E. standard error; CI confidence interval.
Unstandardized 
regression 
coefficients 95% CI for B
Standardized regression 
coefficients
P value r2 r2 changeB S.E Lower limit Upper limit Beta
Non obese OSA patients
Leptin level (ng mL−1) 2.180 0.717 0.760 3.601 0.269 0.001 0.091 0.091
AHI  (h−1) 0.156 0.074 0.011 0.302 0.188 0.036 0.125 0.034
Constant − 1.737 2.862 − 7.406 3.931 – 0.545 – –
Obese OSA patients
Leptin level (ng ml−1) 3.993 1.263 1.466 6.520 0.381 0.002 0.145 0.145
Constant − 6.749 5.609 − 17.971 4.474 – 0.234 –
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our results suggest that the potential contribution of OSA to melanoma aggressiveness is limited to non-obese 
patients (Fig. 5). This finding concurs with the results from a murine subcutaneous melanoma model, in which 
the application of intermittent hypoxia mimicking OSA increased the growth of melanoma tumors in lean mice, 
but not in obese  mice43. In fact, the increased tumor growth induced by obesity was not enhanced by adding the 
intermittent hypoxia stimulus, and the effect of intermittent hypoxia on tumor necrosis, and vascular density 
was dampened in the context of  obesity43. Likewise, a previous analysis of the entire cohort of melanoma patients 
used in the present study showed that the probability of having a Breslow index > 1 mm in patients with an AHI 
or a desaturation index in the upper tertile compared with the reference group was higher in non-obese than in 
obese  patients1. Although our results do not provide a mechanistic explanation for this finding, we speculate that 
the lack of a relationship between sleep parameters and active TGF-β1 levels in obese patients with OSA might 
be attributable to the obesity-induced activation of the NFkB pathway, which could attenuate the OSA-induced 
HIF-1α -TGF-β production pathway. On the other hand, we also cannot rule out competition for binding at 
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specific sites of the TGF-β1 regulatory gene between transcription factors induced by the activation of the leptin 
receptor and by the increase of HIF-1α.
In addition to its multicenter character and the relatively large cohort size, as well as the homogenization and 
rigorous control of sleep studies performed by the Spanish Sleep Network, we believe that the main strength of 
this study was the measurement of free active TGF-β1 in serum, which more reliably reflects effector activity of 
its several biological functions, such as activating epithelial mesenchymal transition, proliferation and the spread 
of  metastasis44. However, our study has several limitations that must be acknowledged. First, the sleep study 
was performed using respiratory polygraphy rather than polysomnography, and it is therefore not possible to 
evaluate the contribution of sleep fragmentation. Second, there was a certain delay between the skin biopsy and 
polygraphic studies (which was not different between the study groups and never exceeded 4 months). Although 
no changes in patient weight or any other potential confounding factors were identified, we cannot rule out that 
such factors were void of any influence on our results. Third, as in most studies recruiting patients who had not 
been referred to sleep units for suspicion of OSA, daytime sleepiness in the OSA groups is low, which may be 
a limitation to extrapolate our findings to much more symptomatic patients. Fourth, we did not have a group 
of patients with distant metastatic melanoma to evaluate their serum TGF-β1 and leptin levels. Fifth, our study 
does not provide any information on the effect of OSA treatment on TGF-β1 levels or its effect on melanoma 
aggressiveness, and therefore no therapeutic recommendations beyond those in place for OSA can be formulated.
In summary, our study shows that melanoma patients with moderate-severe OSA have higher serum levels 
of active TGF-β1, which are directly related to melanoma aggressiveness. Furthermore, in non-obese patients 
with OSA TGF-β1 level variance is dependent on both AHI and serum leptin levels, while in obese patients with 
OSA only leptin levels retain their independent association with TGF-β1 levels.
Methods
Study subjects. Adult patients with new diagnoses of cutaneous melanoma were consecutively selected 
from a multicenter, observational study involving 29 teaching hospitals in  Spain1. Exclusion criteria included 
extra-cutaneous location of the melanoma, daytime respiratory or heart failure, and current or previous use of 
home oxygen therapy, continuous positive airway pressure (CPAP) or noninvasive mechanical ventilation. Out 
of 443 recruited patients, serum samples were obtained in 360 subjects and after their clinical use, were avail-
able in 290 patients. The study was approved by the Institutional Ethics Committee of the Hospital Universitario 
y Politécnico La Fe, Valencia, Spain (2016/0223), and all subjects gave their written informed consent. All the 
experiment protocol for involving humans was in accordance to Declaration of Helsinki.
Dermatological evaluation. As previously  described45,46, patients were evaluated by a dermatologist 
at each hospital, and data for tumor location and clinical stage at diagnosis (categorized as localized or loco-
regional disease) were registered. All tumors were surgically removed, and the Breslow tumor thickness, ulcera-
tion, tumor mitotic rate, and Clark levels were  calculated47. Melanoma growth rate was calculated as the Breslow 
index divided by the difference between the date of the tumor excision and the date on which patients noticed 
changes suggestive of malignant transformation in a stable, pre-existing lesion or the time when they noticed the 
Figure 4.  Supernatant levels of active TGF-β1 in melanoma cells treated with human leptin protein 
concentration at 5 ng mL−1 or 10 ng mL−1 under normoxia or intermittent hypoxia conditions (n = 7). 
Comparison of protein levels between groups was performed by one way ANOVA with multiple Turkey 
comparison. Error bars: SEM. **p < 0.01.
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appearance of a new and changing  lesion46. All dermatological and pathological evaluations were blinded to the 
sleep study and biochemical analysis findings.
Sleep study. Anthropometric characteristics were measured and, according to WHO criteria, obesity was 
defined as a body mass index (BMI) ≥ 30 kg m−2. Simultaneously, all patients underwent overnight respiratory 
polygraphy within a maximum of 4 months after CM diagnosis. All scoring and readings were conducted manu-
ally by experienced and trained personnel. Apnea was defined as an interruption of oronasal flow of > 10  s. 
Hypopnea was defined as a 30–90% reduction in the oronasal airflow for > 10 s associated with an oxygen desatu-
ration ≥ 3%. The apnea–hypopnea index (AHI) was defined as the number of apneas plus hypopneas per hour 
of recording, while tSat90 was defined as the percentage of recording time with  SaO2 < 90%. In addition, mean 
saturation, minimum saturation and oxygen desaturation index (ODI) were measured. According to the AHI, 
patients were divided into three groups: non-OSA (AHI 0–5 h−1), mild OSA (AHI 5–15 h−1) and moderate-
severe OSA (AHI > 15 h−1)48.
Determination of serum levels of active TGFβ1 and leptin. Fasting venous blood samples were 
drawn between 8 and 9 am. The blood samples were centrifuged to separate the serum, and all specimens were 
immediately aliquoted, frozen and stored at − 80 °C. Free active TGF-β1 and leptin in serum were assayed using 
human free active TGF-β1 and leptin enzyme linked immunosorbent assay (437707 Legend Max, San Diego, 
USA and MBS9501873 MyBiosource, San Diego, USA, respectively) according to the manufacturers’ instruc-
tions. The assays were done in duplicates in all samples. The detection limits of the assays were 63 pg mL−1 and 
2.3 pg mL−1, respectively. The intra-assay and inter-assay variations were below 10% in all cases.
Cell culture. C81-61 human cutaneous melanoma cell  line49 was cultured under normoxia or intermittent 
hypoxia (IH) conditions over night, as previously  described50. The culture medium was supplemented with 
human leptin (230-30112-10, RayBiotech) at either a concentration similar to that detected in patients or two-
Figure 5.  Schematic representation of the proposed interaction between intermittent hypoxia, obesity, 
and circulating levels of TGF-ß in patients with melanoma and OSA. In non-obese subjects, OSA-induced 
intermittent hypoxia could have a synergistic effect with leptin produced by adipocytes on the TGF-ß expression 
by melanoma cells, promoting greater tumor aggressiveness. According to the data of the present study, this 
effect is lost in obese patients, since the basal overexpression of TGF-ß caused by high levels of leptin is not 
enhanced by the additional presence of intermittent hypoxia.
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fold that level (5 and 10 ng mL−1, respectively). Supernatant concentrations of active TGF-β1 were measured by 
ELISA as in serum.
RNA isolation, quantification, and analysis. Total RNA was purified using the High Pure RNA Iso-
lation Kit (Ambion, Carlsbad, CA, USA). cDNA was obtained using the High Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems). Gene expression levels were analyzed by real-time quantitative PCR using 
the LightCycler System (Roche Diagnostics, Basel Switzerland); and quantitative PCR was performed using a 
QuantiMix Easy SYG Kit (Biotools; Madrid, Spain). The results were normalized to the expression of 18S, and 
the cDNA copy number of each gene of interest was determined using a 7-point standard curve. The products 
were amplified using specific primers as described  previously20. The products were amplified using primers for 
TGF-β1 5′-GGC CAG ATC CTG TCC AAG C-3′ (forward) and 5′- GTG GGT TTC CAC CAT TAG CAC-3′ (reverse).
Statistical analysis. According the type and distribution of the variables, data are expressed as mean ± SD, 
median (interquartile range [IQR]) or absolute numbers and percentages. Normality was explored using the 
Shapiro–Wilk and skewness-kurtosis tests. Differences between groups were analyzed using the Chi-squared 
or Fisher’s exact tests (categorical variables) and Kruskal–Wallis or Mann–Whitney U tests (ordinary or non-
normal metric variables). For between-group comparisons, TGF-β1 and leptin levels were adjusted for gender, 
age, body mass index and neck circumference using general linear models. Correlations between parameters 
were evaluated using Spearman’s correlation. Those variables exhibiting statistically significant findings were 
then introduced into a multiple linear regression analysis to identify independent determinants of TGF-β1 lev-
els. Stepwise methods were used to include or remove individual independent variables at each step, based on 
the probability of F (entry: 0.05; removal: 0.10). Other aspects explored included residual standard deviation, 
changes in the distribution of the residuals and the homogeneity of the variance over the  predictors51. Analyses 
were performed using the Statistical Package for the Social Sciences (version 20.0; SPSS, Chicago, IL, USA).
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